

## DAFTAR PUSTAKA

- Aapro MS., Cameron DA., Pettengell R., Bohlius J, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. *European Journal of Cancer*. 2006. 42; 2433–2453.
- Aarts MJ., Peters FJ., Mandigers CM., et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. *J Clin Oncol*. 2013. 31 (34): 4290-6. doi: 10.1200/JCO.2012.44.6229.
- Abdullah MM., Mohamed Ak, Foo YC., Lee CML., et al. Breast Cancer Survival at a Leading Cancer Centre in Malaysia. *Asian Pac J Cancer Prev*. 2015. 16 (18), 8513-8517.
- Agiro A, Ma Q, Acheson AK, Wu SJ., Patt DA., Barron JJ., Malin JL., Rosenberg A, Schilsky RL., Lyman GH. Risk of neutropenia related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. *J Clin Oncol*. 2016. 19:19.
- Ahmed JH., Makonnen E, Yimer G, Seifu D. CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose. Intensity in Ethiopian Breast Cancer Patients. 2019. *Frontiers in Pharmacology*. volume 10. [www.frontiersin.org](http://www.frontiersin.org).
- Ashour A, El-Husseiny G, Aziz AA., Arafat WO. First Cycle Neutrophil Count and Subsequent Chemotherapy Dose Delivery in Breast Cancer Patients Receiving Adjuvant Chemotherapy. *Journal of Cancer Therapy*. 2014. 5, 172-178. <http://dx.doi.org/10.4236/jct.2014.52021>.
- Barpe DR., Rosa DD., Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. *Eur J Pharm Sci*. 2010. 41(3-4): 458-63.
- Bonadonna G., Valagussa P. Dose response effect of adjuvant chemotherapy in breast cancer. *The New England Medical Journal of Medicine*. 1981. 304. No.1. 10-5.
- Bronchud MH., Howell A., Crowther D. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. *British Journal of Cancer*. 1989. 60: 121-125.
- Callens C, Mebled M, Stalain de Lord, Veyret, V. Etienne Brain. High-through put pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to

- elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. *Breast Cancer Res Treat.* 2015. 153: 383–389.
- Caroll, et al. 2012. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer. *Breast Cancer Res Treat.* 2012. 136: 323–330.
- Chambers P, Jani Y, Wei L, Kipps E., Forster MD, Wong ICK. Patient factors and their impact on neutropenic events: a systematic review and meta-analysis. *Supportive Care in Cancer.* 2019. 27: 2413–2424.
- Chao C, Page JH., Yang SJ., Rodriguez R, Huynh J., Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. *Annals of Oncology.* 2014. 25: 1821–1829. doi:10.1093/annonc/mdu203.
- Chen K., Zhang X., Deng H., et al. Clinical Predictive Models for Chemotherapy-Induced Febrile Neutropenia in Breast Cancer Patients: A Validation Study. 2014. *PLoS ONE* 9(6): e96413. doi:10.1371/journal.pone.0096413.
- Chen Y, Shi Y, Yan H., Wang YR Dai GH. Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy. *Oncotarget.* 2017. Vol. 8, (No. 39), pp: 66593-66600.
- Coleman, Manuela Quaresma, Franco Berrino, Jean-Michel Lutz, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol.* 2008. 9: 730–56.
- Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Publish Date: August 9, 2006.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017.
- Crawford J., Dale DC., Lyman GH. Chemotherapy induced neutropenia: risks, consequences, and new directions for its management. *Cancer.* 2004. 100, 228–237.
- Crawford J, Armitage J, Balducci L, et al. NCCN Guidelines Version 2.2013 Panel Members Myeloid Growth Factors. 2013. *NCCN.org.*
- Crea F, Giovannetti E, Zinzani PL., Danesi R. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. *Critical Reviews in Oncology/Hematology.* 2009. 72; 21–44.
- Culakova E, Poniewierski MS., Wolff DA., et al. The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. *SpringerPlus.* 2015.4: 396.

- Eldridge SM., Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. *Int J Epidemiol.* 2006. 35 (5): 1292-300.
- Flores IQ., Ershler W. Managing Neutropenia in Older Patients with Cancer Receiving Chemotherapy in a Community Setting. *Clin J Oncol Nurs.* 2010. 14 (1): 81–86. doi: 10.1188/10.CJON.81-86.
- Furuya Y. Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system. *PLOS ONE.* 2019. <https://doi.org/10.1371/journal.pone.02155762019>.
- Georgiou KR., Foster BK., Xian CJ. Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling. *Current Molecular Medicine.* 2010. 10, 440-453.
- Hanley MJ., Abernethy DR., Greenblatt DJ. Effect of Obesity on the Pharmacokinetics of Drugs in Humans. *Clin Pharmacokinet.* 2010; 49 (2): 71-87.
- Hurria AR., Mohile S, Gajra A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. *J Clin Oncol.* 2016. 34 (20): 2366–2371.
- Iked M, Tsuji D, Yamamoto K, Kim YI, et al. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. *Drug Metabolism and Pharmacokinetics.* 2014.
- Ikesue H, Watanabe H, Hirano M, et al. Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. *Biol. Pharm. Bull.* 2015. 38, 1192–1198.
- Jang SH., Kim SY., Kim JH., Park S, Hwang YI, Kim DG., Jung KS. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine plus-platinum-treated patients. *J Cancer Res Clin Oncol.* 2013.:409–417. 139
- Jenkins P, Elyana S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. *European Journal of Cancer.* 2007. 43: 544 – 548.
- Jenkins P, Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy

- for breast cancer. *Annals of Oncology*. 2009. 20: 34–40. doi: 10.1093/annonc/mdn560.
- Jenkins P., Scaife J., Freeman S. Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. *Annals of Oncology*. 2012. 23: 1766–1771. doi:10.1093/annonc/mdr493.
- Jones SE., Savin MA., Holmes FA., et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. *J Clin Oncol*. 2006. 24: 5381-5387.
- Keswara MA., Sudarsa IW., Golden, N. The risk factor of neutropenia on locally advance breast cancer patients treated with first cycle cyclophosphamide, doxorubin, 5-fluorouracil chemotherapy at Sanglah General Hospital Denpasar, Bali-Indonesia. *Bali Medical Journal (BMJ)*. 2012. Volume 1, Number 3: 116-120
- Klastersky J, Awada A, Paesmans M, Aoun M. Febrile neutropenia: A critical review of the initial management. *Critical Reviews in Oncology/ Hematology*. 2011. 78; 185–194.
- Klastersky J, de Naurois J, Rolston K, Rapoport B, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. *Annals of Oncology*. 2016. 27 (Supplement 5): v111–v118.
- Kondo M, Oshita F, Kato Y, Yamada K, Nomura I, Noda K. Early monocytopenia after chemotherapy as a risk factor for neutropenia. *Am J Clin Oncol*. 1999. 22: 103-105.
- Kurtin S. Myelotoxicity on cancer treatment. *AdvancedPractitioner.com*. 2012. Vol 3; 4.
- Lee J, Ahn MH., Jang YH., Lee EJ., et al. Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis. *Breast Cancer*. 2014. 21: 670–676. DOI 10.1007/s12282-013-0442-x.
- Lee JS., Lee HY., Sung NS., Cheon, KW. Predictive factor for excessive myelosuppression in patients receiving chemotherapy for breast cancer. *Korean Journal of Clinical Oncology*. 2016. 12: 55-59. <http://dx.doi.org/10.14216/kjco.16009>.
- Li LJ., Chong, Wang L., et al. Different treatment efficacies and side effects of cytotoxic chemotherapy. *J Thorac Dis*. 2020. 12(7): 3785-3795.
- Lipshultz SE., Adams MJ., Colan, SD., Constine, LS., et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive

cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. *Circulation*. 2013. 128, 1927-95.

Lopez-Pousa, Rifa J, Casas de Tejerina A, Gonzalez-Larriba JL., et al. Risk assessment model for first-cycle chemotherapy induced neutropenia in patients with solid tumours. *European Journal of Cancer Care*. 2010. 19, 648–655.

Lyman GH., Dale DC., Crawford J. Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. *Journal of Clinical Oncology*. 2003. Vol 21, No 24. pp 4524-4531.

Lyman GH., Lyman CH., Agboola O. Risk Models for Predicting Chemotherapy-Induced Neutropenia. *The Oncologist*. 2005. 10: 427–437.

Lyman GH., Kuderer NM., Crawford J. Predicting Individual Risk of Neutropenic Complications in Patients Receiving Cancer Chemotherapy. *Cancer*. 2011. 117: 1917–27.

Ma RM., Chen CZ., Zhang W, You J, Huang DP., Guo GL. Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer. *Medicine*. 2016. Vol.95; 13.

Maccio A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood*. 2005. Volume 106, No. 1.

Martin M, Lluch A, Seguí MA., Antón A, Ruiz A., et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study. *Journal of Clinical Oncology*. 2016. 22, No. 14\_suppl. 620-620.

Maxwell MB., Maher KE. Chemotherapy-Induced Myelosuppression. *Seminars in Oncology Nursing*. 1992. 8, No 2: pp 113-123

Mittra I, Pal K, Pancholi N, Shaikh A, Rane B, Tidke P, Kirolikar S, Khare NK., Agrawal K, Nagare H. Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin. *Annals of Oncology*. 2017. Volume 28, Issue 9, September, 2119–212. <https://doi.org/10.1093/annonc/mdx318>.

Nakada D, Oguro H, Levi BP., Ryan N, et al. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. *Nature*. 2014. Volume 505, pages555–558.

Netterberg I., Nielsen EI., Friberg LE., · Karlsson MO. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. *Cancer Chemother Pharmacol*. 2017. 80: 343–353.

- Nomura M, Morita Y, Kakiuchi A, et al. The association between chemotherapy-induced febrile neutropenia and breast cancer subtype in Japanese patients. *International Journal of Clinical Pharmacy*. 2019.
- Ouyang Z, Peng D, Dhakal DP. Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma. *Oncology Letter*. 2013. 5: 1736-1740, DOI: 10.3892/ol.2013.1234.
- Pettengell R, Bosly, A., Szucs TD., Jackisch C, *et al.* Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. *British Journal of Haematology*. 2008. 144, 677–685. doi:10.1111/j.1365-2141.2008.07514.x
- Rapoport BL., Aapro M, Paesmans M, van Eeden R, Smit T, Krendyukov A, Klastersky J. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. *BMC Cancer*. 2018. 18:917.
- Redana S., Sharp A., Lote H., et al. Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population. *The Breast*. 2016. 13-18.
- Register kanker Jogja. Registrasi Kanker Berbasis Rumah Sakit Dr Sardito Maret 2018. <http://canreg.fk.ugm.ac.id/laporan-data/rkbr-maret-2018/>.
- Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. *J Support Oncol*. 2003. Nov-Dec;1(4 Suppl 2):18-24.
- Rivera E, Erder MH., Fridman M, Frye D, Hortobagyi GN. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. *Breast Cancer Res*. 2003. 5: R114-R120. DOI 10.1186/bcr618.
- Roché H, Fumoleau P, Spielmann M, Canon JL. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. *J Clin Oncol*. 2006. 24: 5664-5671.
- Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. *Lancet Oncol*. 2010. 11: 165–73.
- Schirm S, Engel C, Loeffler M, Scholz M, et al. Modelling chemotherapy effects on granulopoiesis. *BMC Systems Biology*. 2014. 8:138.
- Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data



- from the INC-EU Prospective Observational European Neutropenia Study. *Support Care Cancer*. 2011. 19: 483–490. DOI 10.1007/s00520-010-0840-y.
- Sharma R, Cunningham D, Smith P, et al. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. *BMC Cancer*. 2009. 9:153.
- Shayne M, Culakova E, Poniewierski MS., Wolff D, Dale DC., Crawford J, Lyman GH. Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy. *Cancer*. 2007. 110:1611–20.
- Shimanuki M, Imanishi Y, Sato Y, et al. Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. *Oncotarget*. 2018. Vol.9. no.27: 18970-84.
- Sinaga ES., Ahmad RA., Hutajulu SH. Analysis of 5-year survival of patients treated for breast cancer at Sardjito Hospital in Yogyakarta province, Indonesia. *Berita Kedokteran Masyarakat*. 2017. Vol 33 (2).
- Smith TJ., Khatcheressian J, Lyman GH., Ozer H, Armitage JO., Balducci L, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *Journal of Clinical Oncology*. 2006. 24, 3187–3205.
- Tang NL., Liao CD., Wang X., et al. Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. *J Cancer Res Clin Oncol*. 2012. DOI 10.1007/s00432-012-1345-5.
- Tsuji D, Ikeda M, Yamamoto K., et al. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study. *Medicine (Baltimore)*. 2016 Nov; 95(44): e5151.
- Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. *Seminars in Oncology. Abstract*. 1997. 24. S13-11-S13-18.
- Wang Y, Chen Y, Yin H, Gu X, Shi Y, Dai G. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study. *Cancer Medicine*. 2018; 7(4): 997–1005.
- Yano R., Konno A., Watanabe K, et al. Pharmacoethnicity of docetaxel-induced severe neutropenia integrated analysis of published phase II and III trials. *Int J Clin Oncol*. 2013. 18:96–104.

- Yau TS., Ng TY., Soong IS., et al. Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients – the Hong Kong experience. *Asia-Pacific Journal of Clinical Oncology*. 2009. 5: 123–128.
- Ye X, Zhai Q, Wang ZY., Du Q, Zhu B, Yu B. Neutropenic complications in Chinese patients with breast cancer in a real-world setting. *Int J Clin Exp Pathol*. 2017. 10(1): 651-660.